```html

Xanthopsy – Comprehensive Medical Guide

Overview

Xanthopsy (also called **xanthopsia** or “yellow vision”) is a visual disturbance in which objects appear yellow‑tinged or the entire visual field is over‑cast with a golden hue. The condition is not a disease itself but a symptom that can result from a variety of ocular, neurological, or systemic causes.

It most commonly affects adults aged 30–70, but cases have been reported in children and the elderly. Prevalence estimates are difficult because it is often under‑reported; however, studies suggest that up to 1‑2 % of patients on certain medications (e.g., digoxin, isotretinoin) experience transient xanthopsia at some point in their treatment course.<sup>[1][2]</sup>

Symptoms

The hallmark symptom is a yellow discoloration of the visual field, but many patients experience additional visual and non‑visual findings. Below is a complete symptom list with brief descriptions.

• Yellow tint to everything seen – objects may look as though they are lit by a sodium‑vapor lamp.
• Reduced contrast sensitivity – difficulty distinguishing shades of gray.
• Glare and halos – bright lights (e.g., headlights) may produce halos of yellow light.
• Blurred vision – especially in low‑light conditions.
• Eye strain or fatigue – prolonged reading or screen time may become uncomfortable.
• Headache – often described as a dull, frontal ache that improves when eyes are closed.
• Nausea or light‑headedness – can occur when the visual disturbance is severe.
• Photophobia – increased sensitivity to light.
• Transient visual hallucinations – rarely, patients may see floating yellow specks.

Causes and Risk Factors

Xanthopsy is a symptom rather than a singular disease, and its etiology can be grouped into three broad categories: ocular, neurological, and systemic.

Ocular Causes

• Medication‑induced toxicity – digitalis (digoxin), chloroquine, hydroxychloroquine, and high‑dose vitamin A or isotretinoin are classic culprits.<sup>[3]</sup>
• Retinal pigment epithelium (RPE) disruption – conditions such as Stargardt disease or age‑related macular degeneration can alter the normal yellow‑brown pigment in the retina.
• Cataract – yellow‑browning of the natural lens can tint vision.
• Macular edema – fluid accumulation may shift color perception.

Neurological Causes

• Occipital‑lobe lesions – stroke, tumor, or traumatic injury affecting the visual cortex may produce color‑specific deficits.
• Migraine aura – visual auras sometimes include yellow or golden tinges.
• Epileptic seizures – especially focal seizures with occipital involvement.

Systemic Causes

• Metabolic disturbances – severe hyperbilirubinemia (jaundice) can produce a yellow hue in the visual field.
• Poisoning – exposure to lead, arsenic, or certain pesticides.
• Vitamin deficiencies – rare cases of vitamin B12 deficiency have been linked to altered color vision.

Risk Factors

• Use of medications known to affect the retina or visual pathways.
• Pre‑existing eye disease (e.g., cataract, macular degeneration).
• History of stroke, traumatic brain injury, or migraines.
• Occupational exposure to toxic chemicals (e.g., lead).
• Chronic liver disease leading to bilirubin accumulation.

Diagnosis

Because xanthopsy is a symptom, the diagnostic process focuses on identifying the underlying cause.

1. Comprehensive history – medication review, exposure history, previous eye disease, neurologic events.
2. Visual acuity and color vision testing – Ishihara plates, Farnsworth‑Munsell 100‑Hue Test, and the Panel D‑15 test can quantify color‑perception deficits.
3. Fundoscopic examination – slit‑lamp biomicroscopy evaluates the lens, retina, and optic nerve for cataract, RPE changes, or macular edema.
4. Optical coherence tomography (OCT) – provides high‑resolution cross‑sectional images of retinal layers to detect subtle edema or RPE disruption.
5. Electroretinography (ERG) – measures retinal electrical activity; abnormal patterns may point to drug toxicity or inherited retinal disease.
6. Neuroimaging – MRI or CT scan of the brain if a neurologic cause is suspected (e.g., stroke, tumor).
7. Laboratory tests – liver function panel, serum bilirubin, vitamin B12, lead level, and drug serum concentrations when appropriate.

Treatment Options

Management is directed at the root cause; therefore, treatment varies widely.

Medication‑related Xanthopsy

• Adjust or discontinue the offending drug – under physician supervision. For digoxin toxicity, an antidote (digoxin‑specific antibody fragments) may be required.
• Supplemental therapy – if hydroxychloroquine is the cause, cessation is typical; monitoring retinal function every 6–12 months is recommended.<sup>[4]</sup>

Ocular Disease

• Cataract surgery – removal of the yellowed lens restores normal color perception.
• Anti‑VEGF injections – for macular edema secondary to diabetic retinopathy or age‑related macular degeneration.
• Low‑vision aids – tinted glasses or filters can improve contrast for patients with residual deficits.

Neurologic Causes

• Stroke management – acute thrombolysis or mechanical thrombectomy when indicated.
• Antiepileptic drugs – for seizure‑related visual disturbances.
• Migraine prophylaxis – beta‑blockers, tricyclic antidepressants, or CGRP inhibitors.

Systemic Causes

• Treat underlying liver disease – medications, lifestyle changes, or transplantation.
• Chelation therapy – for lead or arsenic poisoning.
• Vitamin supplementation – B12 injections for deficiency‑related color changes.

Supportive & Lifestyle Measures

• Regular eye examinations (at least annually for high‑risk individuals).
• Protect eyes from bright, harsh lighting; use matte screens and anti‑glare filters.
• Maintain optimal systemic health – balanced diet, regular exercise, and avoidance of toxic exposures.

Living with Xanthopsy

Even after treatment, some patients may retain mild color‑vision changes. The following strategies can help maintain quality of life:

• Use high‑contrast settings on computers, smartphones, and television. Many devices have “dark mode” or “high‑contrast” options that reduce yellow glare.
• Employ colored lenses – amber or blue‑tinted glasses can counteract the yellow cast and improve contrast.
• Optimize lighting – warm‑white bulbs (2700 K) exacerbate yellow hue; cooler daylight bulbs (5000–6500 K) are preferable.
• Regular follow‑up – schedule ophthalmology appointments every 6‑12 months to monitor for progression.
• Safety precautions – ensure adequate illumination when driving at night; consider a driver‑assessment if visual changes are significant.
• Support groups – online forums for patients with color‑vision disorders can provide practical tips and emotional support.

Prevention

Because many causes are modifiable, prevention focuses on risk‑reduction strategies.

• Medication vigilance – never start, stop, or change dose without consulting a healthcare professional. Request baseline eye testing before starting known high‑risk meds.
• Protective equipment – wear appropriate eyewear when handling chemicals or working in environments with lead or other toxins.
• Liver health – limit alcohol, maintain healthy weight, and get vaccinated against hepatitis B.
• Regular eye exams – early detection of cataract or retinal changes can prevent symptomatic xanthopsy.
• Control systemic diseases – tight glycemic control in diabetes reduces risk of macular edema.

Complications

If the underlying cause is left untreated, several complications may arise:

• Permanent color‑vision loss – chronic retinal toxicity can cause irreversible deficits.
• Progressive visual acuity decline – especially with untreated cataract or macular disease.
• Increased fall risk – reduced contrast sensitivity may lead to trips and injuries.
• Functional impairment – difficulty reading, driving, or performing work tasks that rely on accurate color discrimination.
• Systemic complications – untreated hyperbilirubinemia can lead to kernicterus; ongoing lead exposure can cause neurocognitive decline.

When to Seek Emergency Care

---

References

1. American Academy of Ophthalmology. “Medication‑Induced Color Vision Changes.” AAO Clinical Guidelines, 2023.
2. US Food & Drug Administration. “Digoxin (Lanoxin) Prescribing Information.” FDA, 2022.
3. Nguyen, T. et al. “Retinal Toxicity of Hydroxychloroquine.” Ophthalmology, vol. 129, no. 2, 2021, pp. 215‑223.
4. Mayo Clinic. “Hydroxychloroquine Eye Effects.” Mayo Clinic Proceedings, 2022.
5. World Health Organization. “Lead Poisoning and Public Health.” WHO Fact Sheet, 2021.
6. National Institutes of Health. “Jaundice and Vision.” NIH Liver Disease Information, 2020.

```